Foamix Announces Results From Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam For Treatment Up To 1 Year; Data Demonstrated 'Generally Favorable' Safety Profile, 81.6% Of Patients Achieved Clear Or Almost Clear Skin At 52 Weeks
Benzinga Newsdesk